ストックスクリーナーアプリを入手
33.16
3.62%
-1.245
アフターアワーズ：
33.16
前日終値:
$34.41
開ける：
$34.55
24時間の取引高:
58,208
Relative Volume:
1.01
時価総額：
$130.61M
収益：
$17,000
当期純損益:
$-31.08M
株価収益率:
-9.9095
EPS:
-3.3463
ネットキャッシュフロー:
$-24.86M
1週間 パフォーマンス:
-9.13%
1か月 パフォーマンス:
+1.22%
6か月 パフォーマンス:
+22.81%
1年 パフォーマンス:
+86.71%
1日の値動き範囲:
$33.15
$37.40
1週間の範囲:
$33.15
$37.41
52週間の値動き範囲:
$14.00
$44.00
Vtv Therapeutics Inc Stock (VTVT) Company Profile
Compare VTVT vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VTVT
Vtv Therapeutics Inc
|
33.16 | 135.51M | 17,000 | -31.08M | -24.86M | -3.3463 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-12 | 開始されました | Evercore ISI | Outperform |
| 2026-01-23 | 開始されました | Roth Capital | Buy |
| 2026-01-05 | 開始されました | TD Cowen | Buy |
| 2025-11-19 | 開始されました | BTIG Research | Buy |
| 2019-05-30 | 開始されました | H.C. Wainwright | Buy |
| 2018-04-10 | ダウングレード | Stifel | Buy → Hold |
| 2018-03-08 | 開始されました | ROTH Capital | Buy |
| 2018-02-08 | 開始されました | Northland Capital | Outperform |
| 2016-09-26 | 開始されました | H.C. Wainwright | Buy |
| 2015-09-04 | 開始されました | Canaccord Genuity | Buy |
| 2015-08-24 | 開始されました | Piper Jaffray | Overweight |
| 2015-08-24 | 開始されました | Stifel | Buy |
すべてを表示
Vtv Therapeutics Inc (VTVT) 最新ニュース
vTv Therapeutics Inc. Q1 2026 Earnings: Massive EPS Surprise Amid Revenue Shortfall and Stock DeclineSenior Analyst Forecasts - Newser
vTv Therapeutics Inc. (VTVT) Q1 2026 Earnings: Massive EPS Surprise Despite No RevenueAnalyst Stock Picks - Newser
VTVT | vTv Therapeutics Inc. Class Insider Trading - Quiver Quantitative
VTVT Technical Analysis | Trend, Signals & Chart Patterns | VTV THERAPEUTICS INC- CL A (NASDAQ:VTVT) - ChartMill
vTv Therapeutics Inc. (NASDAQ:VTVT) Just Beat Earnings: Here's What Analysts Think Will Happen Next - Yahoo Finance
(VTVT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
vTv Therapeutics (VTVT) Q1 2026 Earnings: EPS $1.65 Beats EstimatesRevenue Report - newser.com
vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
TD Cowen Maintains VTv Therapeutics(VTVT.US) With Buy Rating, Maintains Target Price $67 - Moomoo
Analyst Maintains Buy on vTv Therapeutics, Reiterates Unchanged $49 Price Target Amid Progress of Cadisegliatin Program - TipRanks
H.C. Wainwright cuts vTv Therapeutics stock price target to $45 By Investing.com - Investing.com Nigeria
H.C. Wainwright cuts vTv Therapeutics stock price target to $45 - Investing.com
vTv Therapeutics Inc. Files Form 8-K for Class A Common Stock on Nasdaq – Company Information and SEC Filing Details - Minichart
vTv Therapeutics (VTVT) Reports Strong Q1 Revenue and Trial Prog - GuruFocus
Is vTv Therapeutics (VTVT) 322.2% Overvalued After Q1 2026? EPS - GuruFocus
vTv Therapeutics Expands At-The-Market Share Program Capacity - TipRanks
Recent filings by vTv Therapeutics Inc. to the U.S. Securities and Exchange Commission (SEC) show that the company has increased its allocation of Class A common shares issued under the at-the-market offering (ATM) plan to the full amount. - Bitget
vTv Therapeutics (NASDAQ: VTVT) registers $47.5M ATM to fund cadisegliatin - Stock Titan
vTv Therapeutics (VTVT) expands ATM share offering, files Dechert legal opinion - Stock Titan
vTv Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
vTv Therapeutics Inc. 1Q 2026: Revenue $36.8M, Net income $24.1M — 10-Q Summary - TradingView
Licensing windfall lifts vTv Therapeutics (NASDAQ: VTVT) to Q1 2026 profit and stronger cash - Stock Titan
[8-K] vTv Therapeutics Inc. Reports Material Event - Stock Titan
vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
VTv Therapeutics: Q1 Earnings Snapshot - kare11.com
Oral type 1 diabetes drug advances: vTv expects cash through Phase 3 data - Stock Titan
VTv Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
MSN Money - MSN
TradingKey - TradingKey
vTv Therapeutics (VTVT) Projected to Post Earnings on Wednesday - MarketBeat
vTv Therapeutics Inc. (NASDAQ:VTVT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Two new vTv hires get 39,500 stock options at $32 a share - Stock Titan
What vTv Therapeutics (VTVT) is doing to expand margins | Q4 2025: Profit Exceeds ViewsCertified Trade Ideas - Newser
vTv Therapeutics to Participate in Upcoming May Investor Conferences - The Manila Times
vTv Therapeutics lines up two May investor fireside chats - Stock Titan
VTv Therapeutics to Participate in Upcoming May Investor Conferences - marketscreener.com
vTv Therapeutics (NASDAQ:VTVT) Stock Price Passes Below Fifty Day Moving AverageWhat's Next? - MarketBeat
(VTVT) Risk Channels and Responsive Allocation - Stock Traders Daily
Vtv Therapeutics Inc (VTVT) 財務データ
収益
当期純利益
現金流量
EPS
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):